Status:
COMPLETED
STYLE - Symbicort Single Inhaler Therapy vs Conventional Therapy in Treatment of Persistent Asthma
Lead Sponsor:
AstraZeneca
Conditions:
Asthma
Eligibility:
All Genders
12+ years
Phase:
PHASE3
Brief Summary
The purpose of the study is to compare the efficacy of a flexible dose of Symbicort with conventional stepwise treatment according to asthma treatment guidelines in patients with persistent asthma
Eligibility Criteria
Inclusion
- \- Diagnosis of asthma ³ 3 months
- Prescribed daily use of glucocorticosteroids at a dose \> 320 mcg/ day for at least 3 months prior to Visit 1
Exclusion
- Smoking history \> 10 pack-years
- Asthma exacerbation requiring change in asthma treatment during the last 14 days prior to inclusion
- Any significant disease or disorder that my jeopardize the safety of the patient.
- Additional inclusion and exclusion criteria will be evaluated by the investigator.
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2006
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT00252824
Start Date
July 1 2005
End Date
December 1 2006
Last Update
January 24 2011
Active Locations (53)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Quillota, Chile
2
Research Site
Valparaíso, Chile
3
Researh Site
Dubrovnik, Croatia
4
Research Site
Split, Croatia